CHCWM – Cancer & Hematology Centers of West Michigan

ON123300 19-01 (Onconova)

Description:  An Exploratory Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of ON123300 Capsules Administered Orally as Escalating Daily Doses in Patients with Advanced Cancer Relapsed or Refractory to at Least One Prior Line of Therapy.

Mechanism of Action:  CDK4/6 and ARK5 inhibitor (preclinical data shows efficacy in cell lines resistant to approved CDK4/6 inhibitors)

Target Patient Population:   Solid Tumors

Study Design:  Drug is given PO Daily.